No Data
No Data
No Data
10-Q: Quarterly report
ProMIS Neurosciences Inc Files For Shelf Of Up To 22.1M Common Shares By Selling Stockholders
ProMIS Neurosciences Inc Files For Shelf Of Up To 22.1M Common Shares By Selling Stockholders
ProMIS Neurosciences Inc. PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared To Other Amyloid-Beta-Directed Antibodies In Poster Presentation At AD/PD 2023
ProMIS Neurosciences Inc. (TSX:PMN) (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative dis
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
Poster presentation of study highlighting oligomer selectivity of PMN310 compared to that of other amyloid-beta-directed antibodiesTORONTO, Ontario and CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIR
ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
Poster presentation of study comparing oligomer selectivity of PMN310 to that of other amyloid-beta-directed antibodiesTORONTO, Ontario and CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- ProMIS
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) ("ProMIS" or the "Company"), a biotechnology company focused on th
No Data